The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial
Treatment with remdesivir and/or nirmatrelvir/ritonavir was associated with reduced mortality in hospitalized SARS-CoV-2-infected patients during the Omicron era, primarily in unvaccinated individuals without previous infection. Our findings support prioritizing nonimmune individuals for antiviral treatment.
Authors
- Pontus Hedberg (ORCID: https://orcid.org/0000-0003-3153-098X)
- John Karlsson Valik (ORCID: https://orcid.org/0000-0002-4521-1886)
- Robert Dyrdak (ORCID: https://orcid.org/0000-0001-8456-4898)
- Jan Vesterbacka
- Ola Blennow (ORCID: https://orcid.org/0000-0002-7167-7882)
- Pontus Nauclér (ORCID: https://orcid.org/0000-0002-8185-2648)
- Piotr Nowak (ORCID: https://orcid.org/0000-0003-2747-0734)
- Johan Zetterqvist
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.cmi.2025.09.012
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vetenskapsrådet